Bristol Myers Squibb has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 5.8% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria. Environmental criteria include considerations like the environmental impact of the company's products and services, as well as the company's efficiency in terms ...

The Oracle of Omaha is by far the most well-known long-term investor we have alive today, and if you are a newbie, looking into Warren Buffett stocks to sell is a good way to weed out the bad stocks from your portfolio. I believe Berkshire Hathaway (NYSE:BRK-A, NYSE:BRK-B) alone makes for a pretty good starter portfolio, as it acts like an exchange-traded fund with solid growth. However, if you have individual holdings and are targeting more growth, it still makes sense to mirror some of Buffett’s moves.Thi ...

Core Viewpoint - Bristol Myers Squibb (BMY) presents a unique investment opportunity as its stock price has declined nearly 40% over the past year, significantly underperforming the broader healthcare sector [2][4]. Company Overview - BMY operates in the healthcare sector, focusing on pharmaceuticals that address various diseases, including oncology, cardiovascular, and immunology [4]. - The company has a strong history of dividend payments, having issued dividends for 34 consecutive years, with the current yield at approximately 5.8%, the highest in a decade [4][22]. Financial Performance - BMY's revenue for Q1 2024 was reported at $11.9 billion, showing year-over-year growth despite challenges [12]. - The growth segment of BMY's portfolio has increased to $4.8 billion, up from $4.4 billion in the previous year [12]. - Major revenue contributors include Eliquis, generating about $12 billion annually, and Opdivo, which brings in approximately $9 billion [5][6]. Debt and Acquisitions - BMY's long-term debt has risen to $49.5 billion, primarily due to recent acquisitions, including Mirati for $5.8 billion and Karuna Therapeutics for $14 billion [7][8]. - The high debt levels, combined with elevated interest rates, may suppress growth initiatives and create a more conservative financial stance [8][9]. Market Conditions - The current high interest rate environment poses a significant vulnerability for BMY, impacting its stock price negatively [9]. - The company has a strong liquidity position, with cash and cash equivalents totaling $9.3 billion and cash from operations at $13.72 billion [9]. Valuation - BMY's enterprise value to EBITDA ratio is 7.17x, significantly lower than the sector median of 15.87x, indicating potential undervaluation [17]. - A dividend discount model suggests a fair price value of approximately $48 per share, representing an estimated upside of about 15.7% from current levels [20]. Dividend Growth Potential - The dividend has increased at an average rate of 7% since 2018, with a current payout ratio of approximately 35%, supporting the sustainability of the dividend [18][22]. - BMY's commitment to repaying $10 billion of debt over the next two years further solidifies its ability to maintain dividend distributions [23]. Conclusion - BMY is positioned as a strong investment opportunity due to its solid fundamentals, proactive acquisitions, and potential for dividend growth, despite facing challenges from patent expiries and high debt levels [24].

For many investors, especially those who are just building a portfolio, undervalued stocks under $50 hold significant appeal. Investors can start a significant position, in terms of shares owned, for a small investment. But as every investor knows, price and value aren’t the same thing.When many investors think about undervalued stocks, they look for specific metrics. Some investors may examine technical signals, for example, like a stock trading near its 52-week low. Others may search for a favorable price ...

PM Images This was another interesting week as we get closer to the June FOMC meeting. The US core PCE index increased by 0.2%, which was lighter than the consensus estimate of 0.3% in April. This can certainly be looked at as positive, as it's the slowest increase in MoM in 2024, and the last time PCE increased by 0.2% was in December of 2023. The Fed pays close attention to this metric because it takes consumer spending into consideration, whereas CPI is often looked at as a cost of living fluctuation ...

NEW YORK, June 5, 2024 /PRNewswire/ -- Envisagenics, an AI-driven revenue generating biotechnology company focused on discovery and development of novel RNA splicing therapeutics, today announced a Series B fundraising round with participation from existing investors Third Kind Venture Capital, Empire State Development and Red Cell Partners, and new strategic investor Bristol Myers Squibb (NYSE: BMY). Bristol Myers Squibb previously entered into an oncology research collaboration with Envisagenics in 2022. ...

Bristol Myers Squibb (BMY) announced data from three studies evaluating CD19-directed CAR T cell therapy Breyanzi (liso-cel) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.These data include long-term data with three-year follow-up from the late-stage TRANSFORM study of Breyanzi as a second-line treatment in patients with relapsed or refractory large B-cell lymphoma (LBCL). These also include results from a subgroup analysis evaluating the efficacy and safety of Breyanzi by a number ...

Bristol Myers Squibb (BMY) announced data from three studies evaluating CD19-directed CAR T cell therapy Breyanzi (liso-cel) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.These data include long-term data with three-year follow-up from the late-stage TRANSFORM study of Breyanzi as a second-line treatment in patients with relapsed or refractory large B-cell lymphoma (LBCL). These also include results from a subgroup analysis evaluating the efficacy and safety of Breyanzi by a number ...

PM Images I am not a trader, and I make most of my investment decisions based on a long-term time horizon. I can't time the market, and Bristol-Myers Squibb (NYSE:BMY) is a perfect example of an investment that's continued lower despite my long-term investment thesis. BMY looks like a falling knife, and the cuts are getting deeper and deeper. Over the past year, shares of BMY have declined by -36.24% as they fell from the mid $60s to the low $40s. Nothing about the long-term charts is exciting either, as BM ...

The latest trading session saw Bristol Myers Squibb (BMY) ending at $41.77, denoting a +1.65% adjustment from its last day's close. This move outpaced the S&P 500's daily gain of 0.11%. Meanwhile, the Dow experienced a drop of 0.3%, and the technology-dominated Nasdaq saw an increase of 0.56%.The the stock of biopharmaceutical company has fallen by 6.59% in the past month, lagging the Medical sector's gain of 2.86% and the S&P 500's gain of 5.06%.Investors will be eagerly watching for the performance of Bri ...